[CKD-MBD in Peritoneal Dialysis].

Area of Science:

• Nephrology
• Endocrinology
• Bone Metabolism

Background:

• Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a complex systemic complication of chronic kidney disease (CKD).
• Despite established biochemical targets, CKD-MBD management remains challenging in hemodialysis (HD) and peritoneal dialysis (PD) patients.
• Hyperphosphatemia is a significant predictor of cardiovascular and all-cause mortality in these patient populations.

Purpose of the Study:

• To review the challenges and current understanding of mineral and bone metabolism in dialysis patients.
• To highlight the importance of phosphorus and calcium control in improving patient outcomes.
• To explore the bone-cardiac axis and bone quality differences between HD and PD patients.

Main Methods:

• Review of current literature on CKD-MBD in hemodialysis and peritoneal dialysis.
• Analysis of phosphorus and calcium clearance mechanisms in PD (diffusion, convection, ultrafiltration).
• Discussion of the role of residual renal function and bone-derived substances.

Main Results:

• Phosphorus removal in PD is time-dependent and influenced by dialysis modality and membrane characteristics.
• Calcium balance in PD is affected by dialysate calcium levels and ultrafiltration, with positive balance potentially leading to Adynamic Bone Disease.
• While bone histomorphometry shows fewer differences between HD and PD patients than previously thought, PD patients report fewer fractures, possibly due to better bone quality.

Conclusions:

• Achieving therapeutic targets for CKD-MBD remains a significant clinical challenge in dialysis patients.
• Effective management of hyperphosphatemia is crucial for reducing mortality risk.
• Further research into bone quality and the bone-cardiac axis may offer new therapeutic strategies for CKD-MBD.